Key result
sGC modulators reverse pulmonary hypertension, RV hypertrophy, and vascular remodeling in experimental models.
Why the study?
Severe pulmonary hypertension is characterized by vascular remodeling and right heart hypertrophy, and it is unclear whether activation of soluble guanylate cyclase can reverse these changes in experimental models.
Does activation of sGC with Bay58-2667 or Bay41-2272 reverse experimental pulmonary hypertension and vascular remodeling in mice and rats?
Does activation of sGC with Bay58-2667 or Bay41-2272 reverse experimental pulmonary hypertension and vascular remodeling in mice and rats?
Answers are grounded in this paper and cite their sources.
Activation of soluble guanylate cyclase reverses hemodynamic and structural changes in experimental pulmonary hypertension, an effect partially dependent on endogenous nitric oxide.
BACKGROUND: Severe pulmonary hypertension is a disabling disease with high mortality, characterized by pulmonary vascular remodeling and right heart hypertrophy. Using wild-type and homozygous endothelial nitric oxide synthase (NOS3(-/-)) knockout mice with pulmonary hypertension induced by chronic hypoxia and rats with monocrotaline-induced pulmonary hypertension, we examined whether the soluble guanylate cyclase (sGC) stimulator Bay41-2272 or the sGC activator Bay58-2667 could reverse pulmonary vascular remodeling. METHODS AND RESULTS: Both Bay41-2272 and Bay58-2667 dose-dependently inhibited the pressor response of acute hypoxia in the isolated perfused lung system. When wild-type (NOS3(+/+)) or NOS3(-/-) mice were housed under 10% oxygen conditions for 21 or 35 days, both strains developed pulmonary hypertension, right heart hypertrophy, and pulmonary vascular remodeling, demonstrated by an increase in fully muscularized peripheral pulmonary arteries. Treatment of wild-type mice with the activator of sGC, Bay58-2667 (10 mg/kg per day), or the stimulator of sGC, Bay41-2272 (10 mg/kg per day), after full establishment of pulmonary hypertension from day 21 to day 35 significantly reduced pulmonary hypertension, right ventricular hypertrophy, and structural remodeling of the lung vasculature. In contrast, only minor efficacy of chronic sGC activator therapies was noted in NOS3(-/-) mice. In monocrotaline-injected rats with established severe pulmonary hypertension, both compounds significantly reversed hemodynamic and structural changes. CONCLUSIONS: Activation of sGC reverses hemodynamic and structural changes associated with monocrotaline- and chronic hypoxia-induced experimental pulmonary hypertension. This effect is partially dependent on endogenous nitric oxide generated by NOS3.
No takes yet. Share an insight, caveat, or question.
Dumitrascu et al. (2006) studied Pulmonary hypertension. Bay41-2272 or Bay58-2667 was evaluated on Reversal of pulmonary hypertension, right ventricular hypertrophy, and structural remodeling of the lung vasculature. Treatment with sGC activator Bay58-2667 or stimulator Bay41-2272 significantly reduced pulmonary hypertension, right ventricular hypertrophy, and structural remodeling in experimental models.
Synapse has enriched 10 related papers. Consider them for comparative context: